The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.
The Japanese group pays $120m for Anima’s preclinical small-molecule approach.
A rollercoaster year for biopharma ended with investors firmly deciding that the pandemic was an opportunity, not a threat.
An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.
Early data show that Freeline’s project can get factor IX levels into the normal range, but the group is still looking for the “Goldilocks” zone.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
And bleeds seen with the “transformative” project were played down.
Among the upcoming haematology meeting’s non-oncology presentations Uniqure’s haemophilia B gene therapy scores a valuable late-breaker.